Products Rivaroxaban is commercially available in the form of film-coated tablets (Xarelto, Xarelto vascular). It was approved in 2008 as the first agent in the direct factor Xa inhibitor group. Low-dose Xarelto vascular, 2.5 mg, was registered in many countries in 2019. Structure and properties Rivaroxaban (C19H18ClN3O5S, Mr = 435.9 g/mol) is a pure -enantiomer … Rivaroxaban
Products Edoxaban was approved in many countries and in the United States in 2015 in film-coated tablet form (Lixiana, some countries: Savaysa). In Japan, edoxaban was approved as early as 2011. Structure and properties Edoxaban (C24H30ClN7O4S, Mr = 548.1 g/mol) is present in the drug as edoxabantosilate monohydrate, a white to pale yellow powder that … Edoxaban
Products Dabigatran is commercially available in capsule form (Pradaxa). It has been approved in many countries since 2012. It was first approved in 2008. Structure and properties Dabigatran (C25H25N7O3, Mr = 471.5 g/mol) is present in drugs as mesilate and in the form of the prodrug dabigatran etexilate, which is metabolized in the organism by … Dabigatran
Products Direct factor Xa inhibitors are commercially available in the form of film-coated tablets and capsules. In 2008, rivaroxaban (Xarelto) was the first agent in this group to be approved in many countries and in the EU. Today, there are other drugs on the market, which are listed below. Like thrombin inhibitors, these active ingredients … Factor Xa Inhibitors
Products Betrixaban was approved in the United States in 2017 in capsule form (Bevyxxa). The drug has not yet been approved in the EU (Dexxience). Structure and properties Betrixaban (C23H22ClN5O3, Mr = 451.9 g/mol) is present in the drug as betrixaban maleate. It is a pyridine and anthranilamide derivative. Effects Betrixaban has antithrombotic properties. The … Betrixaban
